March 5, 2019
Teijin Pharma said on March 4 that its gout and hyperuricemia treatment febuxostat, known as Feburic in Japan, has been rolled out in China. In China, febuxostat won approval in September 2018. The drug will be marketed by Astellas Pharma’s...read more